Pulmatrix (NASDAQ:PULM) Posts Quarterly Earnings Results

Pulmatrix (NASDAQ:PULM) released its quarterly earnings data on Friday. The biotechnology company reported ($0.32) EPS for the quarter, FiscalAI reports.

Pulmatrix Stock Performance

Shares of NASDAQ PULM traded down $0.02 during trading hours on Friday, reaching $1.25. 17,492 shares of the stock were exchanged, compared to its average volume of 31,072. The firm has a market capitalization of $4.56 million, a price-to-earnings ratio of -0.89 and a beta of 1.94. Pulmatrix has a 52 week low of $1.16 and a 52 week high of $9.37. The stock’s fifty day simple moving average is $1.56 and its 200 day simple moving average is $2.73.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pulmatrix in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Pulmatrix has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pulmatrix stock. DRW Securities LLC bought a new position in shares of Pulmatrix, Inc. (NASDAQ:PULM) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. Institutional investors and hedge funds own 11.84% of the company’s stock.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).